Cargando…
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, there is a lack of understanding of its molecular drivers. Most treatment data are...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
ESMO Open
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519796/ https://www.ncbi.nlm.nih.gov/pubmed/28761723 http://dx.doi.org/10.1136/esmoopen-2016-000101 |
_version_ | 1783251696479109120 |
---|---|
author | Dolly, Saoirse O Migali, Cristina Tunariu, Nina Della-Pepa, Chiara Khakoo, Shelize Hazell, Steve de Bono, Johann S Kaye, Stanley B Banerjee, Susana |
author_facet | Dolly, Saoirse O Migali, Cristina Tunariu, Nina Della-Pepa, Chiara Khakoo, Shelize Hazell, Steve de Bono, Johann S Kaye, Stanley B Banerjee, Susana |
author_sort | Dolly, Saoirse O |
collection | PubMed |
description | Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, there is a lack of understanding of its molecular drivers. Most treatment data are from limited small studies or extrapolated from pleural mesothelioma. Standard treatment includes curative surgery or pemetrexed-platinum palliative chemotherapy. To date, the use of novel targeted agents has been disappointing. Described is the management of two young women with papillary peritoneal mesothelioma with widespread recurrence having received platinum-pemetrexed chemotherapy. Both patients obtained symptomatic and disease benefit with apitolisib, a dual phosphoinositide 3-kinase-mammalian target of rapamycin (PI3K-mTOR) inhibitor for subsequent relapses, with one patient having a partial response for almost 3 years. Both are alive and well 10–13 years from diagnosis. CONCLUSION: These case presentations highlight a subgroup of rare MPeM that behave indolently that is compatible with long-term survival. This series identifies the use of targeted therapies with PI3K-mTOR-based inhibitors as a novel approach, warranting further clinical assessment. Development of prognostic biomarkers is essential to aid identify tumour aggressiveness, help stratify patients and facilitate treatment decisions. |
format | Online Article Text |
id | pubmed-5519796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | ESMO Open |
record_format | MEDLINE/PubMed |
spelling | pubmed-55197962017-07-31 Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy Dolly, Saoirse O Migali, Cristina Tunariu, Nina Della-Pepa, Chiara Khakoo, Shelize Hazell, Steve de Bono, Johann S Kaye, Stanley B Banerjee, Susana ESMO Open Original Research Peritoneal mesothelioma (MPeM) is a scarce abdominal-pelvic malignancy that presents with non-specific features and exhibits a wide clinical spectrum from indolent to aggressive disease. Due to it being a rare entity, there is a lack of understanding of its molecular drivers. Most treatment data are from limited small studies or extrapolated from pleural mesothelioma. Standard treatment includes curative surgery or pemetrexed-platinum palliative chemotherapy. To date, the use of novel targeted agents has been disappointing. Described is the management of two young women with papillary peritoneal mesothelioma with widespread recurrence having received platinum-pemetrexed chemotherapy. Both patients obtained symptomatic and disease benefit with apitolisib, a dual phosphoinositide 3-kinase-mammalian target of rapamycin (PI3K-mTOR) inhibitor for subsequent relapses, with one patient having a partial response for almost 3 years. Both are alive and well 10–13 years from diagnosis. CONCLUSION: These case presentations highlight a subgroup of rare MPeM that behave indolently that is compatible with long-term survival. This series identifies the use of targeted therapies with PI3K-mTOR-based inhibitors as a novel approach, warranting further clinical assessment. Development of prognostic biomarkers is essential to aid identify tumour aggressiveness, help stratify patients and facilitate treatment decisions. ESMO Open 2017-04-12 /pmc/articles/PMC5519796/ /pubmed/28761723 http://dx.doi.org/10.1136/esmoopen-2016-000101 Text en © European Society for Medical Oncology (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Original Research Dolly, Saoirse O Migali, Cristina Tunariu, Nina Della-Pepa, Chiara Khakoo, Shelize Hazell, Steve de Bono, Johann S Kaye, Stanley B Banerjee, Susana Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy |
title | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy |
title_full | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy |
title_fullStr | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy |
title_full_unstemmed | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy |
title_short | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy |
title_sort | indolent peritoneal mesothelioma: pi3k-mtor inhibitors as a novel therapeutic strategy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519796/ https://www.ncbi.nlm.nih.gov/pubmed/28761723 http://dx.doi.org/10.1136/esmoopen-2016-000101 |
work_keys_str_mv | AT dollysaoirseo indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT migalicristina indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT tunariunina indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT dellapepachiara indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT khakooshelize indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT hazellsteve indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT debonojohanns indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT kayestanleyb indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy AT banerjeesusana indolentperitonealmesotheliomapi3kmtorinhibitorsasanoveltherapeuticstrategy |